AU2020263238C1 - Mirikizumab for use in a method of treating Crohn's Disease - Google Patents
Mirikizumab for use in a method of treating Crohn's Disease Download PDFInfo
- Publication number
- AU2020263238C1 AU2020263238C1 AU2020263238A AU2020263238A AU2020263238C1 AU 2020263238 C1 AU2020263238 C1 AU 2020263238C1 AU 2020263238 A AU2020263238 A AU 2020263238A AU 2020263238 A AU2020263238 A AU 2020263238A AU 2020263238 C1 AU2020263238 C1 AU 2020263238C1
- Authority
- AU
- Australia
- Prior art keywords
- mirikizumab
- administered
- weeks
- dose
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2023265759A AU2023265759A1 (en) | 2019-04-22 | 2023-11-13 | Mirikizumab for use in a method of treating Crohn's Disease |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962836910P | 2019-04-22 | 2019-04-22 | |
| US62/836,910 | 2019-04-22 | ||
| PCT/US2020/028273 WO2020219314A1 (en) | 2019-04-22 | 2020-04-15 | Mirikizumab for use in a method of treating crohn's disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023265759A Division AU2023265759A1 (en) | 2019-04-22 | 2023-11-13 | Mirikizumab for use in a method of treating Crohn's Disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2020263238A1 AU2020263238A1 (en) | 2021-11-04 |
| AU2020263238B2 AU2020263238B2 (en) | 2023-08-17 |
| AU2020263238C1 true AU2020263238C1 (en) | 2024-02-22 |
Family
ID=70554215
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020263238A Active AU2020263238C1 (en) | 2019-04-22 | 2020-04-15 | Mirikizumab for use in a method of treating Crohn's Disease |
| AU2023265759A Pending AU2023265759A1 (en) | 2019-04-22 | 2023-11-13 | Mirikizumab for use in a method of treating Crohn's Disease |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023265759A Pending AU2023265759A1 (en) | 2019-04-22 | 2023-11-13 | Mirikizumab for use in a method of treating Crohn's Disease |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20220040299A1 (enExample) |
| EP (3) | EP3958897B1 (enExample) |
| JP (3) | JP7297930B2 (enExample) |
| KR (2) | KR20250153865A (enExample) |
| CN (2) | CN119700968A (enExample) |
| AU (2) | AU2020263238C1 (enExample) |
| BR (1) | BR112021018930A2 (enExample) |
| DK (1) | DK3958897T3 (enExample) |
| EA (1) | EA202192532A1 (enExample) |
| ES (1) | ES3075314T3 (enExample) |
| FI (1) | FI3958897T3 (enExample) |
| IL (2) | IL286818B2 (enExample) |
| LT (1) | LT3958897T (enExample) |
| MA (1) | MA55756A (enExample) |
| MX (1) | MX2021012848A (enExample) |
| PT (1) | PT3958897T (enExample) |
| SG (1) | SG11202110619XA (enExample) |
| TW (2) | TWI850365B (enExample) |
| UA (1) | UA128657C2 (enExample) |
| WO (1) | WO2020219314A1 (enExample) |
| ZA (1) | ZA202108094B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI850365B (zh) * | 2019-04-22 | 2024-08-01 | 美商美國禮來大藥廠 | 治療克隆氏症(crohn's disease)的方法 |
| KR20220066831A (ko) | 2020-11-16 | 2022-05-24 | 엔브이에이치코리아(주) | 습기경화형 접착제를 이용한 헤드라이닝 제조방법 및 이에 의해 제조되는 헤드라이닝 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20140049B1 (ar) | 2013-03-08 | 2021-08-17 | Lilly Co Eli | أجسام مضادة ترتبط بـ il-23 |
| US20160031983A1 (en) | 2013-03-15 | 2016-02-04 | Amgen Inc. | Methods for treating crohn's disease using an anti-il23 antibody |
| TWI811716B (zh) * | 2015-09-18 | 2023-08-11 | 德商百靈佳殷格翰國際股份有限公司 | 治療發炎性疾病之方法 |
| WO2018035330A1 (en) * | 2016-08-19 | 2018-02-22 | Janssen Biotech, Inc. | Methods of treating crohn's disease with an anti-nkg2d antibody |
| EP3652539A4 (en) * | 2017-07-10 | 2021-03-31 | Rambam Med-Tech Ltd. | ASSAYS FOR EVALUATING NEUTRALIZING ANTIBODIES IN ORGANIC MEDICINE TREATED PATIENTS AND USES THEREOF IN PERSONALIZED MEDICINE |
| TWI850365B (zh) * | 2019-04-22 | 2024-08-01 | 美商美國禮來大藥廠 | 治療克隆氏症(crohn's disease)的方法 |
-
2020
- 2020-04-14 TW TW109112447A patent/TWI850365B/zh active
- 2020-04-14 TW TW113124301A patent/TW202515610A/zh unknown
- 2020-04-15 FI FIEP20724301.5T patent/FI3958897T3/fi active
- 2020-04-15 KR KR1020257033226A patent/KR20250153865A/ko active Pending
- 2020-04-15 EP EP20724301.5A patent/EP3958897B1/en active Active
- 2020-04-15 EA EA202192532A patent/EA202192532A1/ru unknown
- 2020-04-15 EP EP26176666.1A patent/EP4789714A2/en active Pending
- 2020-04-15 DK DK20724301.5T patent/DK3958897T3/da active
- 2020-04-15 WO PCT/US2020/028273 patent/WO2020219314A1/en not_active Ceased
- 2020-04-15 CN CN202411949868.6A patent/CN119700968A/zh active Pending
- 2020-04-15 AU AU2020263238A patent/AU2020263238C1/en active Active
- 2020-04-15 UA UAA202105413A patent/UA128657C2/uk unknown
- 2020-04-15 CN CN202080030747.5A patent/CN113677366A/zh active Pending
- 2020-04-15 MA MA055756A patent/MA55756A/fr unknown
- 2020-04-15 SG SG11202110619XA patent/SG11202110619XA/en unknown
- 2020-04-15 BR BR112021018930A patent/BR112021018930A2/pt unknown
- 2020-04-15 KR KR1020217034113A patent/KR102869852B1/ko active Active
- 2020-04-15 EP EP26176672.9A patent/EP4778573A2/en active Pending
- 2020-04-15 JP JP2021562882A patent/JP7297930B2/ja active Active
- 2020-04-15 ES ES20724301T patent/ES3075314T3/es active Active
- 2020-04-15 MX MX2021012848A patent/MX2021012848A/es unknown
- 2020-04-15 PT PT207243015T patent/PT3958897T/pt unknown
- 2020-04-15 LT LTEPPCT/US2020/028273T patent/LT3958897T/lt unknown
- 2020-04-15 IL IL286818A patent/IL286818B2/en unknown
-
2021
- 2021-10-21 ZA ZA2021/08094A patent/ZA202108094B/en unknown
- 2021-10-21 US US17/507,414 patent/US20220040299A1/en active Pending
-
2023
- 2023-06-14 JP JP2023097427A patent/JP7761614B2/ja active Active
- 2023-11-13 AU AU2023265759A patent/AU2023265759A1/en active Pending
-
2025
- 2025-07-10 JP JP2025116307A patent/JP2025148449A/ja active Pending
- 2025-10-19 IL IL324048A patent/IL324048A/en unknown
Non-Patent Citations (1)
| Title |
|---|
| Ma, C., et al, 2018. Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn’s disease. Expert Opinion on Investigational Drugs, 27(8), pp.649-660. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023248103B2 (en) | Methods of treating ulcerative colitis | |
| Macaluso et al. | The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases | |
| Armuzzi et al. | Ustekinumab in the management of Crohn’s disease: Expert opinion | |
| IL324048A (en) | Mirikizumab for use in a method of treating crohn's disease | |
| CA3134587C (en) | Mirikizumab for use in a method of treating crohn's disease | |
| EA045979B1 (ru) | Мирикизумаб для применения в способе лечения болезни крона |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 NOV 2023 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 NOV 2023 |
|
| FGA | Letters patent sealed or granted (standard patent) |